1147PPreliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers. (23rd October 2018) - Wermke, M; Alt, J; Kauh, J; Back, J; Salhi, Y; Reddy, V; Barve, M; Ochsenreither, S